Propelled by skyrocketing sales of its breakthrough hepatitis C pills, Gilead Sciences Inc. posted an impressive 68 per cent increase in third-quarter profit and hiked its revenue forecast yet again. The Forest City, California, company has what amounts to a license to print money in its Harvoni, the first once-daily, single-pill regimen for hepatitis C, and predecessor drug Sovaldi, both launched in the last two years.